European Commission Approves New Cholesterol Drug Obicetrapib

The European Commission has approved obicetrapib, a once-daily tablet designed to lower LDL cholesterol and raise HDL cholesterol. The drug will be marketed as Ubeslo and as Evlarco when combined with ezetimibe. This approval marks a significant development in the class of CETP inhibitors, as previous drugs in this category had failed to reach patients. While the cholesterol-lowering data are robust, questions remain about its potential, yet unproven, ability to slow the rise of a blood marker for Alzheimer's disease.